Suchttherapie, an esteemed journal published by GEORG THIEME VERLAG KG, serves as a critical platform within the fields of Applied Psychology and Psychiatry and Mental Health. Established in 2000 and continuing through 2024, this journal is committed to advancing the understanding and treatment of addiction and related psychological issues. Although it currently stands in the Q4 Quartile ranking and is categorized as low percentile in both Scopus Ranks and impact metrics, its significance lies in its dedication to disseminating cutting-edge research and clinical findings that contribute to the evolving landscape of therapeutic practices. Published in Germany, the journal facilitates unlimited access to the vital discourse surrounding mental health and addiction treatment, making it a valuable resource for researchers, professionals, and students alike seeking to enhance their knowledge and skills in this important area of study. As the field continues to grow, Suchttherapie plays a pivotal role in bridging practice with academic rigor, ensuring that readers remain informed on the latest methodologies and insights.

American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society, is a leading scholarly journal dedicated to advancing the fields of critical care and pulmonary medicine. With an impressive impact factor and recognized in the Q1 quartile for both Critical Care and Pulmonary Medicine, this journal is essential reading for researchers, clinicians, and students invested in innovative practices and therapies in respiratory health. Through high-quality, peer-reviewed research articles, the journal addresses significant contemporary issues in respiratory and critical care, offering unparalleled insights and fostering interdisciplinary collaboration. Although the journal adheres to a traditional subscription model, it remains a cornerstone for those wishing to stay at the forefront of medical science in this vital area. With its extensive historical context since its establishment in 1991 and continuous publication spanning through 2024, the journal is committed to promoting discourse and disseminating knowledge that ultimately enhances patient care and clinical outcomes.

DRUGS-EDUCATION PREVENTION AND POLICY is a premier scholarly journal published by Taylor & Francis Ltd, focusing on the critical intersection of drug education, prevention strategies, and policy formulation. Established in 1994 and continuing through its converged years into 2024, this journal holds significant relevance within the health and social sciences fields, with commendable standings reflected in its 2023 category quartile rankings of Q2 in both Health (Social Science) and Medicine (Miscellaneous). With an impact ranking that places it in the 73rd and 67th percentiles respectively, it serves as an influential platform for researchers, professionals, and students to disseminate innovative research, case studies, and policy analyses. Those interested in the complexities of drug-related issues are encouraged to explore the insights provided by this journal, contributing to the ongoing discourse in effective prevention and education practices in the context of drug use and its social implications. Although access to articles is not open, the wealth of knowledge presented is invaluable for academia and policy formulation alike.

Journal of Smoking Cessation, published by HINDAWI LTD, serves as a pivotal platform for research and discourse in the field of smoking cessation and related psychology. With an electronic ISSN of 1834-2612, this open-access journal has been disseminating valuable knowledge since 2021, ensuring that researchers, healthcare professionals, and students have unrestricted access to cutting-edge studies and findings. Based in Australia with an international reach, it engages with a diverse audience committed to understanding the complexities of addiction and mental health, notably ranking in the Q3 category of Psychiatry and Mental Health in 2023. Despite a modest Scopus rank (#376 out of 567), the journal continues to contribute significantly to the literature, providing evidence-based insights and practical solutions for smoking cessation interventions. The converged years from 2006 to 2023 reflect a substantial trajectory of scholarship, making it an essential resource for those dedicated to reducing the prevalence of smoking through innovative research and collaboration.

Tobacco Induced Diseases is a leading open-access journal published by EUROPEAN PUBLISHING, dedicated to advancing research in the critical fields of tobacco-related health issues, epidemiology, and public policy. With an ISSN of 1617-9625, this esteemed journal has been nurturing academic discourse since its inception in 2002, situated in the picturesque backdrop of Heraklion, Crete. Recognized for its rigorous publication standards and impactful contributions, the journal proudly holds a Q1 ranking in Health (Social Science) and consistently ranks within the top quarters for both Medicine (Miscellaneous) and Public Health, Environmental, and Occupational Health. With impressive Scopus rankings, including #67 in Health and #99 in Medicine, it serves as an essential platform for researchers, professionals, and students aiming to understand and address the pressing challenges associated with tobacco use and its long-term health implications. As the journal converges its research coverage from 2009 to 2024, it invites contributions that span multidisciplinary perspectives and innovative approaches to tackling tobacco-induced diseases.

The AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, published by the esteemed American Thoracic Society, is a premier platform dedicated to advancing knowledge in the fields of pulmonary and respiratory medicine, cell biology, and clinical biochemistry. With an impressive impact factor and recognition as a Q1 journal in multiple categories for 2023, it ranks among the top tier of scholarly publications, evidencing its influence and contribution to the scientific community. Since its inception in 1989, the journal has provided a critical forum for researchers and professionals to disseminate innovative findings and pivotal reviews, driving forward the frontiers of respiratory biology. While the journal currently operates under traditional access mechanisms, it seeks to bridge gaps in research by presenting high-quality articles that address vital health challenges. As a key resource for both established researchers and emerging scholars in molecular biology and respiratory science, this journal plays a pivotal role in shaping the future of respiratory health advancements.

Tobacco Prevention & Cessation is a vital open-access journal published by EUROPEAN PUBLISHING, dedicated to advancing knowledge in the fields of public health and tobacco control. Established in 2015, this journal provides a platform for the dissemination of high-quality research aimed at reducing tobacco use and improving cessation strategies worldwide. With an impressive impact across various categories, including a Q1 ranking in Health Professions, the journal is integral to the global health community, highlighting critical issues related to tobacco prevention and cessation practices. Researchers and practitioners can benefit from access to cutting-edge studies designed to inform policies and practices, making this journal an essential resource for those committed to combating tobacco-related health challenges. Operating under an open-access model, Tobacco Prevention & Cessation ensures that impactful research is available to all, furthering its mission of fostering public health education and awareness.

Allergy Asthma & Respiratory Disease is a pioneering journal dedicated to advancing research and clinical practice in the fields of allergy, asthma, and related respiratory diseases. Published by the esteemed Korean Academy of Asthma Allergy & Clinical Immunology, this journal aims to disseminate high-quality, peer-reviewed articles that contribute to the understanding, diagnosis, and treatment of these prevalent health issues. Although it operates under a subscription model, it maintains a robust reputation for being a pivotal resource in respiratory health, attracting authors and researchers worldwide. The journal emphasizes interdisciplinary approaches and encourages submissions that span from molecular biology to public health perspectives, making it a vital platform for professionals, researchers, and students eager to deepen their knowledge in respiratory medicine. With a commitment to fostering academic discourse in South Korea and beyond, Allergy Asthma & Respiratory Disease is positioned as a significant contributor to the global conversation on respiratory health.

Journal of Inflammation-London, published by BMC, is a premier open access journal dedicated to advancing the understanding of inflammation, a critical process underlying numerous diseases including autoimmune disorders, cancer, and cardiovascular conditions. With its inception in 2004, the journal has consistently delivered high-quality research that bridges basic science and clinical applications, maintaining a significant place in the academic community. It holds impressive rankings within the Q2 category for both Cell Biology and Clinical Biochemistry, reflecting its impactful contributions to these fields, where it ranks in the 73rd and 64th percentiles respectively. The journal is committed to open access principles, ensuring that all published articles are freely available to researchers, practitioners, and the global community, thereby fostering collaboration and innovation. Located in the United Kingdom, the journal continues to attract submissions from prominent researchers and institutions worldwide, solidifying its status as an essential resource for the latest developments in inflammation research.

JOURNAL OF DRUG ISSUES, published by SAGE PUBLICATIONS INC, serves as a pivotal platform for researchers and professionals dedicated to the multifaceted exploration of drug-related topics across various fields, including health, medicine, psychiatry, and public health. With an ISSN of 0022-0426 and an E-ISSN of 1945-1369, this esteemed journal has maintained a consistent output since its inception in 1971 and is set to continue its contributions through 2024. Reflecting its high academic standards, it has achieved a Q2 ranking in Health (Social Science) and Q3 rankings in several related categories, underscoring its relevance and influence among scholarly work. The journal is indexed in Scopus, with respectable rankings in various medical and health-related disciplines, highlighting its role as an essential resource for those invested in the vigorous discourse surrounding drug issues. Although not an open-access publication, the journal ensures that access to its extensive research findings remains available to a broad audience, solidifying its importance in advancing knowledge and informing best practices in the field.